Last November, Novartis secured European approval for a gene therapy against a rare form of blindness. Six months later, not a single patient has been treated, illustrating the challenges that drug makers face when trying to sell high-priced, one-time medicines in Europe.
Now, Bluebird Bio (BLUE) is nearing European approval of its first gene therapy for a rare blood disorder. An announcement could come within weeks. On Thursday, the biotech offered new details about its commercial plans, telling investors and analysts at a meeting in New York that it hopes to move faster than Novartis while cautioning against expectations for a flying start.
About the Author Reprints
certainly like your web-site but you have to check the spelling on quite a few of your posts. A number of them are rife with spelling issues and I find it very bothersome to tell the truth nevertheless I will definitely come back again.
http://www.appnetidx.com/2018/the-sims-4-seasons-activation-key-codes-free-serial-keygen/